Osmosis Investment Management UK Ltd Invests $784,000 in Biogen Inc. $BIIB

Osmosis Investment Management UK Ltd acquired a new position in Biogen Inc. (NASDAQ:BIIB) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,629 shares of the biotechnology company’s stock, valued at approximately $784,000.

Several other institutional investors have also added to or reduced their stakes in BIIB. BlackRock Inc. purchased a new stake in shares of Biogen during the 2nd quarter valued at approximately $3,453,878,000. Norges Bank bought a new stake in Biogen during the 4th quarter valued at $464,408,000. Boston Partners purchased a new stake in shares of Biogen during the fourth quarter worth $302,815,000. Deutsche Bank AG purchased a new stake in shares of Biogen during the second quarter worth $193,165,000. Finally, Fred Alger Management LLC boosted its holdings in shares of Biogen by 39,074.8% in the fourth quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock worth $140,576,000 after acquiring an additional 796,735 shares during the period. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Stock Performance

NASDAQ BIIB opened at $218.12 on Tuesday. Biogen Inc. has a 52-week low of $131.52 and a 52-week high of $222.15. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. The company has a market capitalization of $32.23 billion, a P/E ratio of 38.61, a P/E/G ratio of 6.75 and a beta of 0.17. The company has a fifty day moving average of $205.92 and a 200-day moving average of $194.87.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.94 by $0.66. The company had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the business earned $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities research analysts predict that Biogen Inc. will post 12.39 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BIIB has been the topic of a number of recent research reports. Guggenheim increased their price objective on Biogen from $260.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Evercore started coverage on shares of Biogen in a report on Friday, May 15th. They issued an “outperform” rating on the stock. Jefferies Financial Group restated a “buy” rating on shares of Biogen in a research report on Monday, July 13th. Piper Sandler reaffirmed an “overweight” rating on shares of Biogen in a research note on Tuesday, July 14th. Finally, Wolfe Research raised shares of Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective for the company in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $227.07.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.